Results 81 to 90 of about 4,126 (156)

Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi [PDF]

, 2020
Background: RTS,S/AS01, the most advanced vaccine against malaria, is now undergoing pilot implementation in Malawi, Ghana, and Kenya where an estimated 360,000 children will be vaccinated each year. In this study we evaluate RTS,S/AS01 alongside bed net
Mvalo, T., Topazian, H.M., Emch, M., Hudgens, M., Bell, G.J., Tegha, G., Hoffman, I., Loop, M., Kamthunzi, P., Mofolo, I., Juliano, J.J., Bailey, J.A.   +11 more
core   +1 more source

Towards Eradication of Malaria: Is the WHO’s RTS,S/AS01 Vaccination Effective Enough?

Risk Management and Healthcare Policy, 2021
Navneet Arora, Lokhesh C Anbalagan, Ashok K Pannu Postgraduate Institute of Medical Education and Research, Chandigarh, IndiaCorrespondence: Ashok K PannuDepartment of Internal Medicine, Postgraduate Institute of Medical Education and Research, 4th Floor,
Arora N, Anbalagan LC, Pannu AK
doaj  

Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette–Guérin-Vaccinated Adults

Frontiers in Immunology, 2018
Systems biology has the potential to identify gene signatures associated with vaccine immunogenicity and protective efficacy. The main objective of this study was to identify optimal postvaccination time points for evaluating peripheral blood RNA ...
Robert A. van den Berg, Laurane De Mot, Geert Leroux-Roels, Viviane Bechtold, Frédéric Clement, Margherita Coccia, Erik Jongert, Thomas G. Evans, Paul Gillard, Robbert G. van der Most   +9 more
doaj   +1 more source

Application of Modeling Approaches to Explore Vaccine Adjuvant Mode-of-Action

Frontiers in Immunology, 2019
Novel adjuvant technologies have a key role in the development of next-generation vaccines, due to their capacity to modulate the duration, strength and quality of the immune response.
Paul R. Buckley, Paul R. Buckley, Kieran Alden, Margherita Coccia, Aurélie Chalon, Catherine Collignon, Stéphane T. Temmerman, Arnaud M. Didierlaurent, Robbert van der Most, Jon Timmis, Jon Timmis, Claus A. Andersen, Mark C. Coles   +12 more
doaj   +1 more source

A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E.

PLoS ONE, 2012
The candidate malaria vaccine RTS,S/AS01(E) provides significant but partial protection from clinical malaria. On in vitro circumsporozoite protein (CSP) peptide stimulation and intra-cellular cytokine staining of whole blood taken from 407 5-17 month ...
Francis M Ndungu, Jedidah Mwacharo, Domtila Kimani, Oscar Kai, Philippe Moris, Erik Jongert, Johan Vekemans, Ally Olotu, Philip Bejon   +8 more
doaj   +1 more source

The lymphatic immune response induced by the adjuvant AS01 : a comparison of intramuscular and subcutaneous immunization routes

, 2016
The liposome-based adjuvant AS01 incorporates two immune stimulants, 3-O-desacyl-4′-monophosphoryl lipid A and the saponin QS-21. AS01 is under investigation for use in several vaccines in clinical development. i.m. injection of AS01 enhances immune cell
Shi, Wei, de Veer, Michael J., Taubenheim, Nadine, Meeusen, Els N. T., Didierlaurent, Arnaud, Neeland, Melanie R., Collignon, Catherine   +6 more
core   +1 more source

Demonstration of the blood-stage Plasmodium falciparum controlled human malaria infection model to assess the efficacy of the P. falciparum membrane antigen 1 vaccine, FMP2.1/AS01 [PDF]

, 2016
Background:?Models of controlled human malaria infection (CHMI) initiated by mosquito bite have been widely used to assess efficacy of preerythrocytic vaccine candidates in small proof-of-concept phase 2a clinical trials.
Elias, S.C., Nugent, FL, Silk, SE, Sukhtankar, P., Birkett, AJ, Ivinson, K., Vekemans, J., Halstead, F.D., McCarthy, JS, Birkett, A.J., Soisson, L.A., Sukhtankar, P, Roberts, R., Lawrie, A.M., Draper, SJ, Woods, C, Hodgson, S.H., Silk, S.E., Faust, S.N., Elias, SC, Waters, NC, Soisson, LA, De Graaf, H., de Graaf, H, Kathcart, AK, Brown, R.E., Edwards, NJ, Cooke, GS, Dutta, S, Hodgson, SH, Waters, N.C., Brown, RE, Long, CA, Milne, KH, Lawrie, AM, Kathcart, A.K., Ivinson, K, Miura, K, Venkatraman, N., Labbe, GM, Ockenhouse, C.F., Payne, R.O., Draper, S.J., Long, C.A., Labbe, G.M., Hill, A.V.S., Poulton, I.D., Hill, AVS, Douglas, A.D., McCarthy, J.S., Douglas, AD, Payne, RO, Venkatraman, N, Biswas, S., Qabar, A.N., Halstead, FD, Cooke, G.S., Ockenhouse, CF, Rampling, TW, Venkataraman, N., Woods, C., Miura, K., Diggs, C.L., Biswas, S, Williams, NC, Poulton, ID, Vekemans, J, Milne, K.H., Faust, SN, Edwards, N.J., Williams, N.C., Nugent, F.L., Roberts, R, Dutta, S., Qabar, AN, Rampling, T.W., Diggs, CL   +76 more
core   +1 more source

Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01(B) vaccination

, 2020
Background: Vaccines eliciting protective and persistent immune responses against multiple human immunodeficiency virus type 1 (HIV-1) clades are needed.
Jongert, Erik, Leroux-Roels, Isabel, Aerssens, Annelies, Yates, Nicole L., Tomaras, Georgia D., Sawant, Sheetal, Janssens, Michel, Van Der Meeren, Olivier, Koutsoukos, Marguerite, Leroux-Roels, Geert, Roman, Francois, Brackett, Caroline, Debois, Muriel, Seaton, Kelly E., Vela, Doris Mesia   +14 more
core   +1 more source

Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa

Malaria Journal, 2011
Background GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative are working in partnership to develop a malaria vaccine to protect infants and children living in malaria endemic regions of sub-Saharan Africa, which can be delivered through
Macete Eusebio, Abdulla Salim, Owusu-Agyei Seth, Cahill Conor, Ofori-Anyinam Opokua, Lievens Marc, Vekemans Johan, Leach Amanda, Njuguna Patricia, Savarese Barbara, Loucq Christian, Ballou W Ripley   +11 more
doaj   +1 more source

Toll‐like receptor 4 signaling in hematopoietic‐lineage cells contributes to the enhanced activity of the human vaccine adjuvant AS01

, 2019
International audienceThe 3-O-desacyl-4'-monophosphoryl lipid A (MPL) activates immunity through Toll-like receptor 4 (TLR4) signaling. The Adjuvant System AS01 contains MPL and is used in the candidate malaria vaccine and the licensed zoster vaccine ...
Laurye Van Maele, Fougeron, Delphine, Sirard, Jean Claude, van Maele, Laurye, Aurélie Chalon, Didierlaurent, Arnaud, Jean‐Claude Sirard, Cayet, Delphine, Collignon, Catherine, Sirard, Jean‐Claude, Diego Piccioli, Delphine Cayet, Chalon, Aurélie, Delphine Fougeron, Arnaud M Didierlaurent, Piccioli, Diego, Catherine Collignon   +16 more
core   +1 more source